Changes in Circulating Lipids Level over Time After Acquiring HCV Infection: Results from ERCHIVES
Overview
Affiliations
Background: Changes in lipid levels over time after acquiring HCV infection, and how they differ from HCV-uninfected persons are unknown.
Methods: We used ERCHIVES to identify those with a known HCV seroconversion window and persistently negative controls. We excluded subjects with HIV and hepatitis B and those who received lipid lowering agents. Total Cholesterol (TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG) and non-HDL cholesterol were retrieved at yearly intervals and plotted over time.
Results: Among 1,270 HCV+ and 5,070 HCV- subjects, median age [IQR] was 47[37,53] for HCV+ and 52[47,57] for the HCV- group; 69% were White and 91% were males in each group. Mean BMI [SD] was 26.94[6.73] in the HCV+ and 28.15 [5.98] in the HCV- group (P < 0.001). Over a 10-year follow-up period among HCV+ persons, TC decreased by (mean (SD) mg/dL) 12.06(36.95), LDL by 9.22(31.44), TG by 13.58(87.01) and non-HDL-C by 12.55(35.14). Among HCV- persons, TC cholesterol decreased by 4.15(31.21), LDL by 4.16(26.51); TG by 4.42(82.34) and non-HDL-C by 5.78(30.17).
Conclusions: After HCV acquisition, TC, LDL, TG and non-HDL-C progressively decline over time independent of BMI and liver fibrosis. Consequences of lipid changes and the need and optimal timing of lipid lowering therapy in HCV+ persons require further study.
Appleton A, Kuniholm M, Vasquez E, Cohen M, Donohue J, Floris-Moore M AIDS. 2023; 38(5):739-750.
PMID: 38126350 PMC: 10939824. DOI: 10.1097/QAD.0000000000003822.
Hepatitis C virus nonstructural protein 4B induces lipogenesis via the Hippo pathway.
Zou C, Tan H, Zeng J, Liu M, Zhang G, Zheng Y Arch Virol. 2023; 168(4):113.
PMID: 36920600 PMC: 10017664. DOI: 10.1007/s00705-023-05743-4.
Horing M, Peschel G, Grimm J, Krautbauer S, Muller M, Weigand K Int J Mol Sci. 2022; 23(17).
PMID: 36077197 PMC: 9456360. DOI: 10.3390/ijms23179806.
Lipid alterations in chronic liver disease and liver cancer.
Paul B, Lewinska M, Andersen J JHEP Rep. 2022; 4(6):100479.
PMID: 35469167 PMC: 9034302. DOI: 10.1016/j.jhepr.2022.100479.
Apolipoprotein E, a Crucial Cellular Protein in the Lifecycle of Hepatitis Viruses.
Treguier Y, Bull-Maurer A, Roingeard P Int J Mol Sci. 2022; 23(7).
PMID: 35409035 PMC: 8998859. DOI: 10.3390/ijms23073676.